Hyperfine, Inc. to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Hyperfine (Nasdaq: HYPR), creator of the first FDA-cleared portable magnetic resonance brain imaging system - the Swoop® system, has announced its participation in two upcoming investor conferences. The company will present at the BTIG Digital Health Forum on November 25, 2024, and the Mizuho Healthcare Conference in New York on December 11, 2024. Interested parties can schedule one-on-one meetings with management through their BTIG or Mizuho representatives.

GUILFORD, Conn.--(BUSINESS WIRE)-- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced plans to present at the upcoming BTIG Digital Health Forum on Monday, November 25, 2024. Management will also participate in the Mizuho Healthcare Conference in New York, NY, on Wednesday, December 11, 2024.

To schedule a one-on-one meeting with management, please reach out to your BTIG representative, Mizuho representative, or the investor contact below.

About the Swoop® Portable MR Imaging® System

The Swoop® Portable MR Imaging® system is U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. It is a portable, ultra-low-field magnetic resonance imaging device for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. The Swoop® system also has CE certification in the European Union and UKCA certification in the United Kingdom. The Swoop® system is commercially available in a select number of international markets.

About Hyperfine, Inc.

Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit hyperfine.io.

The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241113448935/en/

Investor Contact

Webb Campbell

Gilmartin Group LLC

webb@gilmartinir.com

Source: Hyperfine, Inc.

FAQ

When will Hyperfine (HYPR) present at the BTIG Digital Health Forum in 2024?

Hyperfine (HYPR) will present at the BTIG Digital Health Forum on Monday, November 25, 2024.

Which investor conferences will Hyperfine (HYPR) attend in late 2024?

Hyperfine (HYPR) will attend the BTIG Digital Health Forum on November 25 and the Mizuho Healthcare Conference in New York on December 11, 2024.

How can investors schedule meetings with Hyperfine (HYPR) management at the upcoming conferences?

Investors can schedule one-on-one meetings with Hyperfine management through their BTIG or Mizuho representatives.

What is Hyperfine's (HYPR) main product mentioned in the announcement?

Hyperfine's main product is the Swoop® system, the first FDA-cleared portable magnetic resonance brain imaging system.